BidaskClub cut shares of Amyris (NASDAQ:AMRS) from a sell rating to a strong sell rating in a report issued on Tuesday.

Several other research firms have also issued reports on AMRS. HC Wainwright set a $15.00 price target on shares of Amyris and gave the stock a buy rating in a research report on Monday, September 17th. B. Riley set a $10.00 price target on shares of Amyris and gave the stock a buy rating in a research report on Wednesday, October 3rd. Zacks Investment Research lowered shares of Amyris from a hold rating to a sell rating in a research report on Thursday, August 9th. Finally, ValuEngine upgraded shares of Amyris from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has a consensus rating of Buy and a consensus price target of $7.63.

Amyris stock opened at $3.56 on Tuesday. The company has a market capitalization of $264.63 million, a price-to-earnings ratio of -1.17 and a beta of 0.27. Amyris has a 1 year low of $3.11 and a 1 year high of $9.28.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.96). The business had revenue of $14.90 million for the quarter, compared to analysts’ expectations of $46.72 million. The business’s revenue was down 38.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.81) EPS. Equities analysts forecast that Amyris will post -1.34 EPS for the current year.

In other news, COO Eduardo Alvarez acquired 11,877 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The stock was purchased at an average price of $8.45 per share, with a total value of $100,360.65. Following the purchase, the chief operating officer now owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John Melo sold 5,195 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $7.50, for a total transaction of $38,962.50. Following the completion of the transaction, the insider now directly owns 743,713 shares of the company’s stock, valued at approximately $5,577,847.50. The disclosure for this sale can be found here. Insiders own 21.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of AMRS. BlackRock Inc. boosted its stake in Amyris by 139.2% in the 1st quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 31,083 shares during the period. Millennium Management LLC acquired a new position in Amyris in the 1st quarter worth approximately $1,643,000. Engineers Gate Manager LP acquired a new position in Amyris in the 2nd quarter worth approximately $413,000. Rhumbline Advisers acquired a new position in Amyris in the 2nd quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp boosted its stake in Amyris by 87.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,216 shares of the biotechnology company’s stock worth $678,000 after purchasing an additional 49,628 shares during the period. 28.87% of the stock is owned by hedge funds and other institutional investors.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

See Also: Google Finance Portfolio

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.